Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Fortis group gets CCI...

    Fortis group gets CCI green light for internal reorganisation

    Written by savita thakur thakur Published On 2016-10-25T11:25:04+05:30  |  Updated On 25 Oct 2016 11:25 AM IST
    Fortis group gets CCI green light for internal reorganisation
    New Delhi : The Competition Commission of India (CCI) has given its green light to the multi-layered reorganisation involving Fortis group companies.


    Under the deal, Fortis will be carrying out the rejig that involves three entities Fortis Healthcare Ltd (FHL), Fortis Malar Hospitals Ltd (FMHL) and SRL Ltd (SRL).


    In a tweet, the CCI said it has approved the "combination involving internal reorganisation of the Fortis group".


    According to the notice submitted to the fair trade regulator, there would be three "inter-linked and inter-dependent" steps under the rejig.




    FMHL will be off-loading its healthcare business to FHL as a slump sale on a going concern basis for a certain consideration. Then, FHL will demerge its diagnostics business as well as investment/shareholding in SRL into FMHL, according to the notice.


    In the final step, SRL will be amalgamated into FMHL following which the latter's name will be changed to SRL Ltd.

    The composite scheme was cleared by the respective boards of the three companies in August.

    Besides, the watchdog has cleared RPG Life Sciences' acquisition of assets of Sun Pharmaceutical Industries and Sun Pharma Laboratories.

    Separately, CCI has approved the transfer of Raghunathpur power plant to the new joint-venture (JV) between NLC India and Damodar Valley Corporation (DVC).

    DVC will be transferring the 1,200 Mw Raghunathpur power plant in West Bengal to the JV. This will be done as a slump sale on a going concern basis.


    CCICCI green lightCompetition Commission of IndiaDamodar Valley CorporationDVCFortisFortis Malar Hospitalsjoint ventureRPG LifeSRL LtdSun Pharma
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok